Suppr超能文献

相似文献

1
A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus.
J Am Acad Dermatol. 2011 May;64(5):903-8. doi: 10.1016/j.jaad.2010.04.039. Epub 2011 Feb 25.
2
Interventions for pemphigus vulgaris and pemphigus foliaceus.
Cochrane Database Syst Rev. 2009 Jan 21(1):CD006263. doi: 10.1002/14651858.CD006263.pub2.
3
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
4
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Cochrane Database Syst Rev. 2020 Jan 9;1(1):CD011535. doi: 10.1002/14651858.CD011535.pub3.
5
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2.
6
Immunosuppressive treatment for proliferative lupus nephritis.
Cochrane Database Syst Rev. 2018 Jun 29;6(6):CD002922. doi: 10.1002/14651858.CD002922.pub4.
7
Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews.
Cochrane Database Syst Rev. 2017 Jan 13;1(1):CD010369. doi: 10.1002/14651858.CD010369.pub2.
8
Interventions for idiopathic steroid-resistant nephrotic syndrome in children.
Cochrane Database Syst Rev. 2016 Oct 11;10(10):CD003594. doi: 10.1002/14651858.CD003594.pub5.
9
Non-biologic, steroid-sparing therapies for non-infectious intermediate, posterior, and panuveitis in adults.
Cochrane Database Syst Rev. 2022 Oct 31;10(10):CD014831. doi: 10.1002/14651858.CD014831.pub2.

引用本文的文献

2
Rituximab-induced serum sickness in immunobullous disorders: A case series.
Clin Case Rep. 2024 Jul 7;12(7):e9152. doi: 10.1002/ccr3.9152. eCollection 2024 Jul.
3
Autoimmune blistering diseases treated with glucocorticoids: An international study of steroid-induced myopathy.
J Eur Acad Dermatol Venereol. 2025 Feb;39(2):340-349. doi: 10.1111/jdv.20149. Epub 2024 May 31.
4
Senear-Usher syndrome in a 5-year-old girl.
Postepy Dermatol Alergol. 2024 Apr;41(2):242-244. doi: 10.5114/ada.2024.139233. Epub 2024 Apr 25.
5
Quality of systematic reviews on the treatment of vesiculobullous skin diseases. A meta-epidemiological study.
An Bras Dermatol. 2024 Mar-Apr;99(2):223-232. doi: 10.1016/j.abd.2023.06.003. Epub 2023 Nov 18.
7
A Case of Severe Bullous Dermatitis With Mixed Bullous Pemphigoid and Pemphigus Vulgaris Cutaneous Manifestations.
Cureus. 2021 Dec 15;13(12):e20433. doi: 10.7759/cureus.20433. eCollection 2021 Dec.
10
Survival of Adjuvant Drugs for Treatment of Pemphigus: A Population-based Cohort Study.
Acta Derm Venereol. 2021 Sep 3;101(9):adv00535. doi: 10.2340/00015555-3831.

本文引用的文献

1
Reliability and convergent validity of two outcome instruments for pemphigus.
J Invest Dermatol. 2009 Oct;129(10):2404-10. doi: 10.1038/jid.2009.72. Epub 2009 Apr 9.
2
Interventions for pemphigus vulgaris and pemphigus foliaceus.
Cochrane Database Syst Rev. 2009 Jan 21(1):CD006263. doi: 10.1002/14651858.CD006263.pub2.
3
Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus.
J Am Acad Dermatol. 2008 Jun;58(6):1043-6. doi: 10.1016/j.jaad.2008.01.012. Epub 2008 Mar 14.
5
Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris.
J Am Acad Dermatol. 2007 Oct;57(4):622-8. doi: 10.1016/j.jaad.2007.05.024. Epub 2007 Jun 21.
6
Introducing a novel Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) in pemphigus.
Eur J Dermatol. 2007 Jan-Feb;17(1):4-11. doi: 10.1684/ejd.2007.0090. Epub 2007 Feb 27.
7
Accelerating effects of epidermal growth factor on skin lesions of pemphigus vulgaris: a double-blind, randomized, controlled trial.
J Eur Acad Dermatol Venereol. 2007 Jan;21(1):79-84. doi: 10.1111/j.1468-3083.2006.01873.x.
8

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验